Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164943
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Iglesias, Pablo | - |
dc.contributor.author | Ribero, Simone | - |
dc.contributor.author | Barreiro Capurro, Alicia | - |
dc.contributor.author | Podlipnik, Sebastian | - |
dc.contributor.author | Carrera Álvarez, Cristina | - |
dc.contributor.author | Malvehy, J. (Josep) | - |
dc.contributor.author | Puig i Sardà, Susana | - |
dc.date.accessioned | 2020-06-09T11:38:34Z | - |
dc.date.available | 2020-06-09T11:38:34Z | - |
dc.date.issued | 2019-02-01 | - |
dc.identifier.issn | 0001-5555 | - |
dc.identifier.uri | http://hdl.handle.net/2445/164943 | - |
dc.description.abstract | Talimogene laherparepvec (T-VEC) (Imlygic, Amgen) is the first oncolytic virus approved for use in therapy for metastatic melanoma. T-VEC provides a treatment option for patients with limited metastatic disease. T-VEC is a genetically modified, live, attenuated herpes simplex virus type 1 designed to replicate in tumour cells and promote an enhanced anti-tumour response (1) T-VEC is administered by injection into cutaneous, subcutaneous or nodal lesions, which are visible and/or palpable and/ or visualized by ultrasonography (2). Other local management options have been used to control metastatic disease in stage IIIB, but almost all have shown only a local effect and rapid disease relapse (3, 4). With T-VEC, responses occurred in injected and uninjected lesions, including a greater than 50% decrease in size in 15% of uninjected visceral lesions. The appearance of vitiligo has been described as an adverse event after administration of immune checkpoint inhibitors (5, 6). It has been reported as a marker of activity of the drug and long-term results, inducing clinicians to use it as a predictor of drug response (7). A T-VEC phase II study has reported 85% adverse events, all of which were grade 1 or 2. The appearance of vitiligo has been described in 3 patients out of 50 (8), although no details regarding duration and appearance have been reported. | - |
dc.format.extent | 2 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Society for the Publication of Acta Dermato-Venereologica | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2340/00015555-3061 | - |
dc.relation.ispartof | Acta Dermato-Venereologica, 2019, vol. 99, num. 2, p. 232-233 | - |
dc.relation.uri | https://doi.org/10.2340/00015555-3061 | - |
dc.rights | (c) Iglesias, Pablo et al., 2019 | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Càncer de pell | - |
dc.subject.classification | Vitiligen | - |
dc.subject.classification | Melanoma | - |
dc.subject.other | Skin cancer | - |
dc.subject.other | Vitiligo | - |
dc.subject.other | Melanoma | - |
dc.title | Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 688464 | - |
dc.date.updated | 2020-06-09T11:38:34Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
688464.pdf | 713.41 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.